134303-96-1 Usage
General Description
FMOC-PRO-PRO-PRO-OH is a chemical compound consisting of three proline amino acids linked together by peptide bonds and attached to a 9-fluorenylmethyloxycarbonyl (FMOC) protecting group. FMOC-PRO-PRO-PRO-OH is commonly used in peptide synthesis and solid-phase peptide synthesis as a building block for the creation of longer peptide chains. The FMOC protecting group can be removed with a suitable reagent, allowing the peptide to be further elongated or used for various biological and chemical studies. Additionally, the proline residues in the structure contribute to the compound's conformational properties and potential biological activities. Overall, FMOC-PRO-PRO-PRO-OH plays a significant role in peptide chemistry and drug development research.
Check Digit Verification of cas no
The CAS Registry Mumber 134303-96-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,4,3,0 and 3 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 134303-96:
(8*1)+(7*3)+(6*4)+(5*3)+(4*0)+(3*3)+(2*9)+(1*6)=101
101 % 10 = 1
So 134303-96-1 is a valid CAS Registry Number.
134303-96-1Relevant articles and documents
Hybrid bombesin analogues: Combining an agonist and an antagonist in defined distances for optimized tumor targeting
Kroll, Carsten,Mansi, Rosalba,Braun, Friederike,Dobitz, Stefanie,Maecke, Helmut R.,Wennemers, Helma
, p. 16793 - 16796 (2013)
Radiolabeled hybrid ligands with defined distances between an agonist and an antagonist for the gastrin-releasing peptide receptor were found to have excellent tumor-targeting properties. Oligoprolines served as rigid scaffolds that allowed for tailoring distances of 10, 20, and 30 A between the recognition elements. In vitro and in vivo studies revealed that the hybrid ligand with a distance of 20 A between the recognition elements exhibits the highest yet observed tumor cell uptake and retention time in prostate cancer cells.
